Bringing the very best science and medicine to our best equine friends
May 1, 2017

Kindred Biosciences Announces Initiation of Enrollment in Pivotal Effectiveness Trial of Zimeta Oral for the Control of Fever in Horses

San Francisco, CA (May 1, 2017) Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that the first patient has been enrolled in the pivotal effectiveness trial evaluating its novel, oral formulation of Zimeta™ (dipyrone oral gel) for the control of fever in horses. “We are very pleased to announce initiation of enrollment in our pivotal effectiveness trial for Zimeta Oral. This milestone brings us one step closer to bringing this innovative oral gel to owners and veterinarians and reflects continued progress of our rich pipeline,” stated Richard Chin, M.D., …

Continue Reading